dbo:abstract
|
- Sitaxentan (Handelsname: Thelin®, Hersteller: , eine Tochterfirma des Pfizer-Konzerns) ist ein Endothelin-Rezeptorantagonist und war als Alternative zu Ambrisentan und Bosentan als so genanntes Orphan-Arzneimittel zur Behandlung des seltenen Lungenbluthochdrucks (Pulmonale Hypertonie, NYHA-Stadium III) zugelassen. (de)
- Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH). It was marketed as Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity. (en)
|
dbo:bioavailability
| |
dbo:casNumber
|
- 184036-34-8
- 210421-64-0 (sodium salt)
|
dbo:chEMBL
| |
dbo:drugbank
| |
dbo:fdaUniiCode
| |
dbo:kegg
| |
dbo:pubchem
| |
dbo:thumbnail
| |
dbo:wikiPageExternalLink
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 7953 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:atcPrefix
| |
dbp:atcSuffix
| |
dbp:bioavailability
| |
dbp:c
| |
dbp:casNumber
| |
dbp:casSupplemental
| |
dbp:chembl
| |
dbp:chemspiderid
| |
dbp:cl
| |
dbp:drugbank
| |
dbp:eliminationHalfLife
| |
dbp:excretion
| |
dbp:h
| |
dbp:innEma
| |
dbp:iupacName
|
- N--2-4,5-(methylenedioxy)-o-tolyl]acetyl]-3-thiophenesulfonamide (en)
|
dbp:iupharLigand
| |
dbp:kegg
| |
dbp:legalStatus
| |
dbp:licenceEu
| |
dbp:metabolism
| |
dbp:n
| |
dbp:o
| |
dbp:proteinBound
| |
dbp:pubchem
| |
dbp:routesOfAdministration
| |
dbp:s
| |
dbp:smiles
|
- Cc1cc2OCOc2cc1CCc3sccc3SNc4oncc4Cl (en)
|
dbp:synonyms
| |
dbp:unii
| |
dbp:width
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
gold:hypernym
| |
rdf:type
| |
rdfs:comment
|
- Sitaxentan (Handelsname: Thelin®, Hersteller: , eine Tochterfirma des Pfizer-Konzerns) ist ein Endothelin-Rezeptorantagonist und war als Alternative zu Ambrisentan und Bosentan als so genanntes Orphan-Arzneimittel zur Behandlung des seltenen Lungenbluthochdrucks (Pulmonale Hypertonie, NYHA-Stadium III) zugelassen. (de)
- Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH). It was marketed as Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity. (en)
|
rdfs:label
|
- Sitaxentan (de)
- Sitaxentan (en)
|
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:depiction
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |